0001104659-19-065130.txt : 20191118 0001104659-19-065130.hdr.sgml : 20191118 20191118170811 ACCESSION NUMBER: 0001104659-19-065130 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191115 FILED AS OF DATE: 20191118 DATE AS OF CHANGE: 20191118 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Farzaneh-Far Ramin CENTRAL INDEX KEY: 0001688195 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37926 FILM NUMBER: 191228259 MAIL ADDRESS: STREET 1: 87 CAMBRIDGEPARK DRIVE STREET 2: C/O RA PHARMACEUTICALS, INC. CITY: CAMBRIDGE STATE: MA ZIP: 02140 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Ra Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001481512 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 262908274 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 87 CAMBRIDGE PARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 BUSINESS PHONE: (617) 401-4060 MAIL ADDRESS: STREET 1: 87 CAMBRIDGE PARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 4 1 a4.xml 4 X0306 4 2019-11-15 0 0001481512 Ra Pharmaceuticals, Inc. RARX 0001688195 Farzaneh-Far Ramin C/O RA PHARMACEUTICALS, INC. 87 CAMBRIDGEPARK DRIVE CAMBRIDGE MA 02140 0 1 0 0 Chief Medical Officer COMMON STOCK 2019-11-15 4 M 0 1389 5.60 A 8521 D COMMON STOCK 2019-11-15 4 M 0 9206 5.60 A 17727 D COMMON STOCK 2019-11-15 4 S 0 10595 46.6559 D 7132 D Stock Options (Right to buy) 5.60 2019-11-15 4 M 0 1389 0 D 2026-08-16 Common Stock 1389 16666 D Stock Options (Right to buy) 5.60 2019-11-15 4 M 0 9206 0 D 2026-08-16 Common Stock 9206 110478 D The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 16, 2019. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $46.62 to $46.80. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. These stock options vest over a four (4) year period in 48 equal monthly installments at the end of each month following August 16, 2016. These stock options vest a four (4) year period with the first twenty five percent (25%) of such shares vesting on the first anniversary of July 11, 2016, and the remaining shares vesting in equal monthly installments at the end of each month following the first anniversary of July 11, 2016 over the following thirty six (36) months, subject to the terms set forth in the applicable equity agreement. /s/ David Lubner, Attorney-in-Fact for Ramin Farzaneh-Far 2019-11-18